OPKO Health (OPK) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of a loss of $0.10 per share. This compares to loss of $0.11 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 130%. A quarter ago, it was expected that this holding company with investments in pharmaceutical and diagnostics companies would post a loss of $0.09 per share when it actually produced a loss of $0.01, deliverin ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024. OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Securities registered pursuant to Section 12(b) of the Act: | --- | --- | |---------------------------------------------------------------------------|------------------- ...

Exhibit 99.1 OPKO Health Reports Third Quarter 2024 Business Highlights and Financial Results Conference call begins at 4:30 p.m. Eastern time today MIAMI (November 7, 2024) – OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and nine months ended September 30, 2024. Highlights from the third quarter of 2024 and recent weeks include the following: ● Completed sale of select assets of BioReference Health to Labcorp for $237.5 million. OPKO completed the sale of B ...

OPKO Health, Inc.'s (OPK) company, ModeX Therapeutics Inc., was awarded $35 million of additional funding under an existing contract with the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response at the U.S. Department of Health and Human Services on Monday. The funding brings the total support awarded to ModeX to $110 million out of $205 million if all options are executed. The funding is expected to support the development of a s ...

Brings total awards from BARDA to $110 million for development of broad SARS-CoV-2 and Influenza multispecifics, with potential funding of up to $205 million if all options are executed Development work is based on ModeX proprietary MSTAR technology that incorporates multiple antibody binding sites into a single molecule WESTON, Mass., Oct. 07, 2024 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health, Inc. (NASDAQ: OPK) company, announces it has been awarded $35 million of additional funding under a ...

OPKO Health, Inc. (OPK) is well-poised for growth in the coming quarters, courtesy of its potential in RAYALDEE. The optimism surrounding the stock is backed by RAYALDEE's performance and strategic partnerships. However, stiff competition and overdependence on RAYALDEE are concerns. Shares of this Zacks Rank #3 (Hold) company have lost 1.3% year to date against the industry's 9.8% growth. The S&P 500 has gained 21% in the said time frame. This renowned multinational biopharmaceutical and diagnostics company ...

OPKO Health, Inc. (OPK) delivered a loss per share of a penny in the second quarter of 2024, narrower than the year-ago period's loss of 3 cents per share and the Zacks Consensus Estimate of a loss of 9 cents per share. Revenues in Detail OPKO Health registered revenues of $182.2 million in the second quarter, down 31.3% year over year. The figure, however, missed the Zacks Consensus Estimate by 1.7%. Lower revenues from products and transfer of intellectual property and other dragged the overall top line. ...

OPKO Health (OPK) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.03 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 88.89%. A quarter ago, it was expected that this holding company with investments in pharmaceutical and diagnostics companies would post a loss of $0.09 per share when it actually produced a loss of $0.12, delivering a surpris ...

OPKO Health, Inc. (NASDAQ:OPK) Q2 2024 Earnings Conference Call August 7, 2024 4:30 PM ET Company Participants Yvonne Briggs – LHA Investor Relations Phillip Frost – Chairman and Chief Executive Officer Elias Zerhouni – Vice Chairman and President Adam Logal – Chief Financial Officer Conference Call Participants Maury Raycroft – Jefferies Yale Jen – Laidlaw and Company Michael Petusky – Barrington Research Operator Good day, and welcome to the OPKO Health Second Quarter 2024 Financial Results Conference Cal ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024. OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Securities registered pursuant to Section 12(b) of the Act: | --- | --- | |---------------------------------------------------------------------------|------------------------ ...